TY - JOUR ID - 120189 TI - Biomarkers for Prostate Cancer Diagnosis from Genetic Perspectives JO - Translational Research in Urology JA - TRU LA - en SN - AU - Khatami, Fatemeh AU - Aghamir, Seyed Mohammad Kazem AU - Salmaninejad, Arash AU - Shivarani, Sepideh AU - Khorrami, Mohammad Hatef AD - Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran AD - Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran AD - Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran Y1 - 2020 PY - 2020 VL - 2 IS - 2 SP - 51 EP - 58 KW - Prostate Cancer KW - Diagnosis KW - Biomarker DO - 10.22034/tru.2020.258970.1053 N2 - Prostate cancers (PC) are mainly diagnosed by screening prostate-specific antigen (PSA) quantity in the blood or a digital rectal exam (DRE). PC typically does not have symptoms contrary to advanced cancers that are diagnosed due to significant symptoms. Diagnosis of PC is established with the transrectal ultrasound (TRUS) guided biopsy. Estimation of the free PSA to total PSA (fPSA/tPSA) ratio and Multiparametric-magnetic resonance imaging (mp-MRI) can expand the diagnosis accuracy. Several molecular biomarkers have improved PC diagnosis like Confirm MDx, Prostate Core Mitomic Test (PCMT), TMPRSS2-ERG, The PTEN gene, ProMark, 4K score including, and Circulating Tumor Cells (CTCs). These molecular biomarkers are considered both genetic and epigenetic (DNA methylation) hallmarks of PC. We aim to present an overview of all molecular biomarkers of PC and their implication in improving the management of PC patients. UR - http://www.transresurology.com/article_120189.html L1 - http://www.transresurology.com/article_120189_95e558ce7e355fb44a09656d304b9616.pdf ER -